Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zochodne, D. W.
Right arrow Articles by Fritzler, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zochodne, D. W.
Right arrow Articles by Fritzler, M. J.
Related Collections
Right arrow All Immunology
Right arrow Autoimmune diseases
Right arrow Peripheral neuropathy
Right arrow Chronic inflammatory demyelinating polyneuropathy

Neurology 2003;60:127-129
© 2003 American Academy of Neurology
Brief Communications

Longstanding ataxic demyelinating polyneuronopathy with a novel autoantibody

Douglas W. Zochodne, MD FRCP, Roland Auer, MD FRCP and Marvin J. Fritzler, MD FRCP

From the Departments of Clinical Neurosciences (Dr. Zochodne), Histopathology (Dr. Auer), and Medicine (Dr. Fritzler), Faculty of Medicine, University of Calgary, Alberta, Canada.

Address correspondence and reprint requests to Dr. Douglas W. Zochodne, Department of Clinical Neurosciences, Faculty of Medicine University of Calgary, 3330 Hospital Dr. NW, Calgary, AB, Canada T2N 4N1; e-mail: dzochodn{at}ucalgary.ca

The authors describe the clinical course, postmortem findings, and characterization of a novel autoantibody (anti-M-phase phosphoprotein-1 [anti-MPP-1]) in a patient with a longstanding acquired demyelinating polyneuropathy and neuronopathy. Postmortem examination identified active sensory neuron degeneration, sensory axon loss, and widespread peripheral nerve demyelination. A possible pathophysiologic role of anti-MPP-1 is not yet identified.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.